Altium Capital Management LLC
Follow13F filer, CIK 1746382, NEW YORK, NY
Altium Capital Management LLC reported $0 across 1 holding for the quarter ended 2025-06-30, in a 13F-HR filed 2025-08-07.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001420506-25-001745
- Period
- 2025-06-30
- Reported value
- $0
- Holdings
- 1
- Top 10 weight
- New
- 1
- Sold out
- 24
Largest buys vs the previous quarter
None.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| ZVRAexited | -1,287,333 | -$9.64M |
| EOLSexited | -296,193 | -$3.56M |
| XTNTexited | -7,252,998 | -$3.41M |
| AVADEL PHARMACEUTICALSexited | -419,131 | -$3.28M |
| CTNMexited | -303,857 | -$2.12M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q2 2025
Share positions as resolved from 13F-HR 0001420506-25-001745, largest first. % of portfolio is the value over $0, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| 00 | 0 | $0 | new | Value filed as zero, left out of ratios.Amount filed as zero, left out of ratios. |
Sold out in Q2 2025
Positions in the previous quarter's report that this quarter's report no longer lists.
| Security | Shares before | Value before | Type |
|---|---|---|---|
| ZVRAZEVRA THERAPEUTICS INC | 1,287,333 | $9.64M | shares |
| ALNYALNYLAM PHARMACEUTICALS INC | 25,000 | $6.75M | put |
| EOLSEVOLUS INC | 296,193 | $3.56M | shares |
| XTNTXTANT MED HLDGS INC | 7,252,998 | $3.41M | shares |
| AVADEL PHARMACEUTICALSAVADEL PHARMACEUTICALS | 419,131 | $3.28M | shares |
| CTNMCONTINEUM THERAPEUTICS INC | 303,857 | $2.12M | shares |
| PROFPROFOUND MED CORP | 360,589 | $2.1M | shares |
| XENEXENON PHARMACEUTICALS INC | 60,251 | $2.02M | shares |
| ESSA PHARMA INCESSA PHARMA INC | 1,050,369 | $1.66M | shares |
| SKYESKYE BIOSCIENCE INC | 904,865 | $1.44M | shares |
| ACOGALPHA COGNITION INC | 177,416 | $898K | shares |
| RZLTREZOLUTE INC | 303,949 | $881K | shares |
| NEKTAR THERAPEUTICSNEKTAR THERAPEUTICS | 1,051,379 | $715K | shares |
| AVRANTERIS TECHNOLOGIES GLOBAL | 168,589 | $614K | shares |
| LRMRLARIMAR THERAPEUTICS INC | 273,204 | $587K | shares |
| PROMIS NEUROSCIENCES INCPROMIS NEUROSCIENCES INC | 574,248 | $399K | shares |
| ENVVENO MEDICAL CORPORATIONENVVENO MEDICAL CORPORATION | 123,256 | $324K | shares |
| XENEXENON PHARMACEUTICALS INC | 9,400 | $315K | call |
| INTELLIGENT BIO SOLUTIONS ININTELLIGENT BIO SOLUTIONS IN | 149,252 | $215K | shares |
| KPTIKARYOPHARM THERAPEUTICS INC | 49,333 | $185K | shares |
| SHARPS TECHNOLOGY INCSHARPS TECHNOLOGY INC | 4,044,149 | $110K | shares |
| LOGICMARK INCLOGICMARK INC | 5,395,308 | $107K | shares |
| SBFMSUNSHINE BIOPHARMA INC | 50,466 | $96.4K | shares |
| SRXHSRX GLOBAL INC | 38,984 | $67.1K | shares |
How Q2 2025 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0001420506-25-001745 | base | 2025-08-07 | acceptance time not in the bulk data set |